Bellerophon Therapeutics, Inc.
Robbins Arroyo LLP Is Investigating the Officers and Directors of Bellerophon Therapeutics, Inc. (BLPH) on Behalf of Shareholders
Robbins Arroyo LLP is investigating whether certain officers and directors of Bellerophon Therapeutics, Inc. (NASDAQGM: BLPH) violated federal securities laws in connection with its initial public offering (“IPO”). Bellerophon, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases.
Bellerophon’s Stock Suffers
On February 13, 2015, Bellerophon held its IPO, selling 13 million shares of stock and raising $60 million in new capital. However, since the IPO, Bellerophon’s stock has fallen drastically from its offering price of $12 per share to close at only $1.17 per share on October 31, 2016. The decline may be due to the fact that the company’s business operations and financial prospects were not as strong as represented in the company’s Registration Statement that it filed with the U.S. Securities and Exchange Commission.
Bellerophon Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.